膀胱尿路上皮癌组织中窖蛋白1的表达及其与患者预后的关系

目的 明确膀胱尿路上皮癌组织中窖蛋白1的表达水平,并探讨其与膀胱尿路上皮癌预后的关系.方法 应用免疫组化法检测85例膀胱尿路上皮癌组织中窖蛋白1的表达,比较其中64例初发者和21例复发者的表达差异,以及窖蛋白阳性和阴性表达初发患者的预后.结果 85例膀胱尿路上皮癌组织中,窖蛋白1表达阳性34例(40.0%).窖蛋白1在初发性和复发性膀胱尿路上皮癌组织中的表达阳性率分别为32.8%和61.9%,差异有统计学意义(P<0.05).21例窖蛋白1阳性表达的初发性膀胱尿路上皮癌患者平均无瘤生存时间为14.2个月,43例窖蛋白1阴性的初发性膀胱尿路上皮癌患者平均无瘤生存时间为18.9个月,两组差异有统计学意义(P<0.05),窖蛋白1阳性表达组的术后无瘤生存率低于阴性表达组(P<0.05).结论 窖蛋白1与膀胱尿路上皮癌的发生有关,其阳件表达是膀胱尿路上皮癌复发的高危因素.

Analysis of the relationship between expression of caveolin-1 and prognosis in bladder transitional cell carcinoma

Objective To analyze the relationship between expressions of caveolin-1 and prognosis in bladder transitional cell carcinoma ( BTCC). Methods The expression of caveolin-1 was detected in 85 cases of BTCC. 64 cases of primary BTCC were followed-up after operation. The tumor-free survival time in recurrent BTCC patients was observed. Results The positive expression rates of caveolin-1 in primary and recurrent BTCC were 32. 8% and 61. 9% , respectively, with a significant difference (P <0. 05). There was a significant difference ( P < 0.05) between the tumor-free survival times in the groups with positive and negative expressions of caveolin-1. The half-, 1-, 2- and 3-year tumor-free survival rates in the group with positive expression of caveolin-1 were 90.4% , 80.9% , 66. 3% and 56. 1% , respectively. The half-, 1-, 2-, and 3-year tumor-free survival rates in the group with negative expression of caveolin-1 were 97.7% , 95.4%, 81.4% and 79.0%, respectively. The tumor-free survival rate in the group with positive expression of caveolin-1 was significantly lower than that in the group with negative expression of caveolin-1 (P<0.05). Conclusion Positive expression of caveolin-1 in BTCC can be regarded as a high risk factor of recurrence of BTCC. Positive expression of caveolin-1 in BTCC is correlated with the prognosis of BTCC, and BTCC patients with positive expression of caveolin-1 should be followed-up after operation.